Long-Term Outcomes and Toxicity of Concurrent Paclitaxel and Radiotherapy for Locally Advanced Head-and-Neck Cancer

International Journal of Radiation Oncology Biology Physics

Volumn 74, Issue 4, 2009, Pages 1040-1046

  Citrin, Deborah ^a   Mansueti, John ^a   Likhacheva, Anna ^a   Sciuto, Linda ^a   Albert, Paul S ^a   Rudy, Susan F ^b   Cooley Zgela, Theresa ^a   Cotrim, Ana ^c   Solomon, Beth ^d   Colevas, A Dimitrios ^e   Russo, Angelo ^a   Morris, John C ^a   Herscher, Laurie ^f   Smith, Sharon ^a   Van Waes, Carter ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS   (United States)

^c NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e STANFORD CANCER INSTITUTE   (United States)

^f SUBURBAN HOSPITAL   (United States)

Author keywords

Head and neck; Paclitaxel; Radiotherapy; Toxicity

Indexed keywords

CONCURRENT CHEMORADIOTHERAPY; EXTERNAL BEAM RADIOTHERAPY; HEAD AND NECK; HEAD-AND-NECK CANCER; LOCAL CONTROL; LOCAL RECURRENCE; LONG-TERM OUTCOME; MEDIAN SURVIVAL; PACLITAXEL; PERCUTANEOUS ENDOSCOPIC GASTROSTOMY; RADIATION FIELD; SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECKS; XEROSTOMIA;

CONCURRENCY CONTROL; RADIOTHERAPY;

TOXICITY;

PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; ESOPHAGUS DISEASE; ESOPHAGUS STRICTURE; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FIBROSIS; FOLLOW UP; HEAD AND NECK CARCINOMA; HUMAN; HYPOTHYROIDISM; MALE; MULTIPLE CYCLE TREATMENT; PERCUTANEOUS ENDOSCOPIC GASTROSTOMY; PHARYNX DISEASE; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RADIATION INJURY; SALIVARY GLAND DISEASE; SQUAMOUS CELL CARCINOMA; TRACHEOSTOMY; TREATMENT OUTCOME; XEROSTOMIA;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; FEASIBILITY STUDIES; FEMALE; FIBROSIS; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PACLITAXEL; PROSPECTIVE STUDIES; RADIATION INJURIES; RADIOTHERAPY DOSAGE; SKIN; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 67649531651     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2008.09.053     Document Type: Article

References (27)

1. Calais G., Alfonsi M., Bardet E., et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 91 (1999) 2081-2086
2. Adelstein D.J., Lavertu P., Saxton J.P., et al. Mature results of a phase III randomized trial comparing concurrent chemoradiotherapy with radiation therapy alone in patients with stage III and IV squamous cell carcinoma of the head and neck. Cancer 88 (2000) 876-883
3. Adelstein D.J., Saxton J.P., Lavertu P., et al. A phase III randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer: Preliminary results. Head Neck 19 (1997) 567-575
4. Abitbol A., Abdel-Wahab M., Lewin A., et al. Phase II study of tolerance and efficacy of hyperfractionated radiotherapy and 5-fluorouracil, cisplatin, and paclitaxel (Taxol) in stage III and IV inoperable and/or unresectable head-and-neck squamous cell carcinoma: A-2 protocol. Int J Radiat Oncol Biol Phys 53 (2002) 942-947
5. Bucci M.K., Rosenthal D.I., Hershock D., et al. Final report of a pilot trial of accelerated radiotherapy plus concurrent 96-hour infusional paclitaxel for locally advanced head and neck cancer. Am J Clin Oncol 27 (2004) 595-602
6. Haddad R., Wirth L., Costello R., et al. Phase II randomized study of concomitant chemoradiation using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with newly diagnosed locally advanced squamous cell carcinoma of the head and neck. Semin Oncol 30 (2003) 84-88
7. Kies M.S., Haraf D.J., Rosen F., et al. Concomitant infusional paclitaxel and fluorouracil, oral hydroxyurea, and hyperfractionated radiation for locally advanced squamous head and neck cancer. J Clin Oncol 19 (2001) 1961-1969
8. Machtay M., Aviles V., Kligerman M.M., et al. A phase I trial of 96-hour paclitaxel infusion plus accelerated radiotherapy of unrespectable head and neck cancer. Int J Radiat Oncol Biol Phys 44 (1999) 311-315
9. Milano M.T., Haraf D.J., Stenson K.M., et al. Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, gemcitabine, and twice-daily radiation in patients with poor-prognosis cancer of the head and neck. Clin Cancer Res 10 (2004) 4922-4932
10. Feher O., Martins S.J., Lima C.A., et al. Pilot trial of concomitant chemotherapy with paclitaxel and split-course radiotherapy for very advanced squamous cell carcinoma of head and neck. Head Neck 24 (2002) 228-235
11. Amrein P.C., Clark J.R., Supko J.G., et al. Phase I trial and pharmacokinetics of escalating doses of paclitaxel and concurrent hyperfractionated radiotherapy with or without amifostine in patients with advanced head and neck carcinoma. Cancer 104 (2005) 1418-1427
12. Rosenthal D.I., Lee J.H., Sinard R., et al. Phase I study of paclitaxel given by seven-week continuous infusion concurrent with radiation therapy for locally advanced squamous cell carcinoma of the head and neck. J Clin Oncol 19 (2001) 1363-1373
13. Sunwoo J.B., Herscher L.L., Kroog G.S., et al. Concurrent paclitaxel and radiation in the treatment of locally advanced head and neck cancer. J Clin Oncol 19 (2001) 800-811
14. Cox J.D., Stetz J., and Pajak T.F. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31 (1995) 1341-1346
15. Navazesh M., and Christensen C.M. A comparison of whole mouth resting and stimulated salivary measurement procedures. J Dent Res 61 (1982) 1158-1162
16. Ship J.A., Fox P.C., and Baum B.J. How much saliva is enough? "Normal" function defined. J Am Dent Assoc 122 (1991) 63-69
17. List M.A., Ritter-Sterr C., and Lansky S.B. A performance status scale for head and neck cancer patients. Cancer 66 (1990) 564-569
18. Simone N.L., Soule B.P., Gerber L., et al. Oral pirfenidone in patients with chronic fibrosis resulting from radiotherapy: A pilot study. Radiat Oncol 2 (2007) 19
19. Allal A.S., Nicoucar K., Mach N., et al. Quality of life in patients with oropharynx carcinomas: Assessment after accelerated radiotherapy with or without chemotherapy versus radical surgery and postoperative radiotherapy. Head Neck 25 (2003) 833-840
20. Magne N., Marcy P.Y., Chamorey E., et al. Concomitant twice-a-day radiotherapy and chemotherapy in unresectable head and neck cancer patients: A long-term quality of life analysis. Head Neck 23 (2001) 678-682
21. Eisbruch A., Lyden T., Bradford C.R., et al. Objective assessment of swallowing dysfunction and aspiration after radiation concurrent with chemotherapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys 53 (2002) 23-28
22. Kotz T., Costello R., Li Y., et al. Swallowing dysfunction after chemoradiation for advanced squamous cell carcinoma of the head and neck. Head Neck 26 (2004) 365-372
23. Specenier P., and Vermorken J.B. The role of taxanes and targeted therapies in locally advanced head and neck cancer. Curr Opin Oncol 19 (2007) 195-201
24. Tishler R.B., Busse P.M., Norris Jr. C.M., et al. An initial experience using concurrent paclitaxel and radiation in the treatment of head and neck malignancies. Int J Radiat Oncol Biol Phys 43 (1999) 1001-1008
25. Agarwala S.S., Cano E., Heron D.E., et al. Long-term outcomes with concurrent carboplatin, paclitaxel and radiation therapy for locally advanced, inoperable head and neck cancer. Ann Oncol 18 (2007) 1224-1229
26. Colevas A.D., Read R., Thornhill J., et al. Hypothyroidism incidence after multimodality treatment for stage III and IV squamous cell carcinomas of the head and neck. Int J Radiat Oncol Biol Phys 51 (2001) 599-604
27. Bentzen S.M., and Trotti A. Evaluation of early and late toxicities in chemoradiation trials. J Clin Oncol 25 (2007) 4096-4103